**Supplementary Table 1** – Clinical parameters and markers of glucose homeostasis, residual beta-cell function and beta-cell autoimmunity during the follow-up period.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Parameter** | **T1D onset** | **2 months after the T1D onset** | **14 months after the T1D onset** | **19 months after the T1D onset** | **24 months after the T1D onset** | **31 months after the T1D onset** |
| **Body weight (Kg)** | 69 | 71.5 | 67.5 | 68.5 | 70.0 | 73.0 |
| **BMI (Kg/m2)** | 22.5 | 23.3 | 22.0 | 22.4 | 22.9 | 23.8 |
| **Blood pressure (mmHg)** | 130/90 | 120/60 | 110/70 | 120/70 | 110/60 | 110/70 |
| **HbA1c (%; mmol/mol)** | 13.2% (121 mmol/mol) | 5.3% (34 mmol/mol) | 5.2% (33 mmol/mol) | 5.7% (39 mmol/mol) | 6.1% (43 mmol/mol) | 6.0% (42 mmol/mol) |
| **Total daily insulin dose (TDI)** | 0.7 IU/ Kg body weight/24 hours (after DKA resolution; basal-bolus insulin therapy) | 0.09 IU/Kg body weight/24 hours (insulin degludec 7 IU/day) | 0.10 IU/Kg body weight/24 hours (insulin degludec 7 IU/day) | 0.10 IU/Kg body weight/24 hours (insulin degludec 7 IU/day) | 0.10 IU/Kg body weight/24 hours (insulin degludec 7 IU/day) | 0.11 IU/Kg body weight/24 hours (insulin degludec 8 IU/day) |
| **IDAA1c** | Not applicable | 5.6 | 5.6 | 6.1 | 6.5 | 6.4 |
| **Arterial blood gas (ABG) test** | pH 7.163; bicarbonate 9.5 mmol/L; sodium 142.1 mmol/L; potassium 4.05 mmol/L; chloride 106 mmol/L; anion gap 30.65 mmol/L | n/a | n/a | n/a | n/a | n/a |
| **Fasting capillary blood ketones (mmol/L)** | >3.0 | 0.3 | 0.2 | 0.3 | 0.4 | 0.3 |
| **Fasting plasma C-peptide (ng/mL)**  **(reference range: 0.78-5.19)** | 0.22 | 0.74 | 0.87 | 0.28 | 0.17 | 0.58 |
| **30-min (MMTT) plasma C-peptide (ng/mL)** | n/a | 1.89 | 1.52 | 0.90 | 0.34 | n/a |
| **60-min (MMTT) plasma C-peptide (ng/mL)** | n/a | 2.53 | 1.62 | 1.25 | 0.70 | n/a |
| **90-min (MMTT) plasma C-peptide (ng/mL)** | n/a | 2.95 | 1.69 | 1.52 | 0.86 | n/a |
| **120-min (MMTT) plasma C-peptide (ng/mL)** | n/a | 2.53 | 1.78 | 2.00 | 1.16 | n/a |
| **Fasting plasma glucose (mg/dL)** | 501 | 80 | 72 | 72 | 74 | 117 |
| **30-min (MMTT) plasma glucose (mg/dL)** | n/a | 203 | 146 | 170 | 146 | n/a |
| **60-min (MMTT) plasma glucose (mg/dL)** | n/a | 151 | 183 | 235 | 243 | n/a |
| **90-min (MMTT) plasma glucose (mg/dL)** | n/a | 110 | 165 | 261 | 283 | n/a |
| **120-min (MMTT) plasma glucose (mg/dL)** | n/a | 81 | 182 | 250 | 326 | n/a |
| **Fasting C-peptide index** | 0.04 | 0.92 | 1.20 | 0.38 | 0.22 | 0.49 |
| **30-min (MMTT) C-peptide index** | n/a | 0.93 | 1.04 | 0.52 | 0.23 | n/a |
| **60-min (MMTT) C-peptide index** | n/a | 1.67 | 0.88 | 0.53 | 0.28 | n/a |
| **90-min (MMTT) C-peptide index** | n/a | 2.68 | 1.02 | 0.58 | 0.30 | n/a |
| **120-min (MMTT) C-peptide index** | n/a | 3.12 | 0.97 | 0.80 | 0.35 | n/a |
| **GADA**  **(reference range: 0.00-5.00 AU/mL)** | **24.6** | n/a | **26.0** | **26.3** | **20.0** | n/a |
| **IAA**  **(reference range: 0.00-9.00 U/mL)** | 5.1 | n/a | 1.8 | 0.4 | 1.3 | n/a |
| **IA2A**  **(cut-off for positivity: ≥7.4 U/mL)** | **>350.0** | n/a | **201.10** | n/a | **350.0** | n/a |
| **ZnT8A**  **(cut-off for positivity: ≥14.9 U/mL)** | **18.9** | n/a | 9.60 | n/a | 2.5 | n/a |
| **ICA**  **(cut-off for negativity - indirect immunofluorescence: <1:5)** | <1:5 | n/a | <1:5 | <1:5 | n/a | n/a |
| **Serum 25-hydroxyvitamin D levels (ng/mL)** | n/a | 28 | 57 | 45 | 50 | 31.4 |

IDAA1c (Insulin-Dose Adjusted HbA1c) was calculated through the following formula: HbA1c (%) + 4 x [insulin dose (units per kilogram per 24 h)]. A calculated IDAA1c value of ≤9 was considered indicative of partial remission [ref. 30]. 120-minute-mixed meal tolerance tests (MMTTs) were performed via oral administration of Ensure Plus®, Abbott (360 mL) for the evaluation of residual beta-cell function. C-peptide index (a.k.a. C-peptide to glucose ratio) was assessed in fasting and (MMTT)-postprandial states, and was calculated through the following formula: C-peptide (ng/mL)/glucose (mg/dL) (×100) [ref. 29]. **Abbreviations**: BMI, body mass index; GADA, glutamic acid decarboxylase autoantibodies; HbA1c, glycated hemoglobin; IAA, insulin autoantibodies; IA2A, islet tyrosine phosphatase 2 autoantibodies; ICA, islet-cell antibodies; IDAA1c, Insulin-Dose Adjusted HbA1c; MMTT, mixed meal tolerance test; n/a, not available; T1D, type 1 diabetes; ZnT8A, zinc transporter 8 autoantibodies.